Discussion of the two biologies of DLBCL – the GCB and ABC subtype and potential targeted therapies
Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
Targeted molecular signatures of DLBCL and upcoming CheckMate 647 trial for PCNSL and PTL
Panel discussion on large cell lymphomas: subtypes, patient selection and mutations
Andrew Zelenetz et al.
Current projects at City of Hope: CAR T-cells, vaccines and a novel nuceloside analogue
Panel discussion on T-cell lymphoma: current status of therapy and progress
Elaine Jaffe et al.
The potential clinical implications of targeted therapies for DLBCL and why the situation is complex